Nasolacrimal Duct Obstruction

Status Completed

Clinical Trial Summary

1.1 Background Obstructions of the lacrimal drainage system can be differentiated based on anatomical location or severity. But also, differentiating between congenital and acquired nasolacrimal duct obstruction (NLDO) is possible. The incidence of congenital NLDO (CNLOD) has been shown to be approximately 20%. Most of the cases undergo spontaneous remission, as the ductus nasolacrimalis may open spontaneously. About 2-12% display a symptomatic course. 2. S: 290; 3; 4, 5 Acquired NLDO may occur during childhood and adulthood. The incidence of symptomatic acquired NLDO is around 30 cases per 100.000 people in an US-based cohort study. S: 293; 30 Two major anatomical closure sites have been described, which are on the one hand located at the between the punctum and canaliculus, and on the other hand located after the lacrimal sac. 1. S. ; 2. S: 293 1.2 Aim of this study The aim of this study is to assess the success rates for different types of primary tear duct surgery, performed from 2013 - 2017 at the department of Ophthalmology and Optometry, Medical University of Vienna. Treatment success was defined as the absence of clinical signs of lacrimal drainage system obstruction (epiphora, increased tear leak, mucous discharge) and without the need for re-intervention. It is further investigated whether the type of operation performed or whether the silicone tube used influence success rates. 1.3 Methods A retrospective chart analysis of all patients - independent of the underlying pathology - undergoing surgery of the lacrimal drainage system between 1st of January 2013 and 31st December 2017. Success rates and patient profiles will be analyzed not only for all patients, but also for subgroups based on the underlying pathology and operation performed.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04931186
Study type	Observational
Source	Medical University of Vienna
Contact
Status	Completed
Phase
Start date	July 3, 2018
Completion date	June 11, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05414994` - Assessment of the Ocular Microbiome in Health and Disease
Active, not recruiting	`NCT04271709` - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)	N/A
Completed	`NCT02811692` - Study for Collection of Aflibercept Data in Routine Practice
Recruiting	`NCT06045299` - Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia	Phase 3
Recruiting	`NCT01521065` - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration	Phase 2
Completed	`NCT04799704` - Tear Film SARS-nCoV-2 Detection in Symptomatic and Pauci-symptomatic Patients.
Recruiting	`NCT05876689` - Swept Source OCT Imaging With the DREAM VG-OCT
Active, not recruiting	`NCT04123626` - A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene	Phase 1/Phase 2
Recruiting	`NCT04150432` - Correlation Between Exhaled Propofol Concentration With Plasma Concentration in Children	N/A
Not yet recruiting	`NCT05550740` - Repeated Low-Level Red-Light Therapy for Shortening Axial Length	N/A
Completed	`NCT02332343` - Sparing of the Fovea in Geographic Atrophy Progression	N/A
Completed	`NCT01727973` - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy	Phase 1/Phase 2
Terminated	`NCT01225146` - Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)	Phase 1
Completed	`NCT00333203` - Next Generation Ophthalmic Irrigating Solution Posterior Segment Study	Phase 3
Not yet recruiting	`NCT05565547` - Multimodal Equipment for Teleophthalmology Assessment (META)
Recruiting	`NCT05158699` - Effectiveness of Periocular Drug Injection in CATaract Surgery	Phase 3
Recruiting	`NCT06112340` - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)	Phase 2/Phase 3
Recruiting	`NCT06451172` - Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis	Early Phase 1
Completed	`NCT05211089` - Manual Versus Automated Choroidal Thickness Measurements Using Swept-source Anterior Segment OCT
Not yet recruiting	`NCT06070467` - Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases